Table of contents

Paper

• STOP-Hypertension-2 and best practice for the future (1 September, 2000)

  Lennart Hannson
• Secondary prevention: improving outcomes following myocardial infarction (1 September, 2000)

  Aldo P Maggioni
• Improving patient outcomes in heart failure: evidence and barriers (1 September, 2000)

  John G F Cleland
• Angiotensin converting enzyme inhibition: from viper to patient (1 September, 2000)

  Michel Komajda, Marie-Catherine Wimart
• Left ventricular dysfunction: causes, natural history, and hopes for reversal (1 September, 2000)

  Paul W Armstrong
• Renin-angiotensin system mediated mechanisms: cardioreparation and cardioprotection (1 September, 2000)

  Christian G Brilla
• Endothelial dysfunction: the role and impact of the renin-angiotensin system (1 September, 2000)

  Thomas F Lüscher
• Managing cardiovascular risk in patients with diabetes (1 September, 2000)

  Lars Rydén
• Diabetic nephropathy: evidence for renoprotection and practice (1 September, 2000)

  Carl-Erik Mogensen
• Modulation of the renin-angiotensin system and retinopathy (1 September, 2000)

  Nish Chaturvedi
• RAS blockade: new possibilities in the treatment of complications of diabetes (1 September, 2000)

  Luis Ruilope
• Modern management of hypertension and heart failure: evidence and practice (1 September, 2000)

  F D Richard Hobbs
• ACE inhibition and AT₁ receptor blockers: efficacy and duration in hypertension

  (1 September, 2000)

  Peter A Meredith
• AT₁ receptor antagonists—beyond blood pressure control: possible place in heart failure treatment

  (1 September, 2000)

  John McMurray
• Lipid lowering: statins and the future (1 September, 2000)

  James Shepherd
• The future: cardiovascular medicine in 10 years (1 September, 2000)

  Karl Swedberg
• Discussion (1 September, 2000)